Innovation Pharmaceuticals Inc (IPIX)

[rr50]

Indeed. If Prurisol equals Otezla as to efficacy - say ~30% PASI 75 in the powered P2b - then it'll be valued in the multiple billions. If it encroaches on the biologics, then watch out. $5-10bn in play. Plenty of Biotechs and Big Rxs would be stepping up to the plate. Sounds like Leo is already in such discussions, what seems to have been signaled today.

See page 15 of the linked to report below. A comprehensive overview of current Psoriasis treatments. Otezla and the Biologics as scored across PASI 75, PASI 50, PASI 90, PASI 100.

https://icer-review.org/wp-content/uploads/2016/12/NE_CEPAC_Psoriasis_Evidence_Report_FINAL_120216.pdf

https://icer-review.org/topic/psoriasis/

Recall also Brilacidin UP/UPS and OM interim findings will be coming online about the same time as the Prurisol P2b readout. Adding further potential Big Number valuations to CTIX.

Kevetrin Ovarian and oral formulation also getting underway.

2017 is setting up to be a pivotal, potentially Partner-rich year.

Question will be if the current studies deliver like many of us longs think they can/will, does Leo get a buyout offer that is too hard to refuse? Might very well be the case.